MEDP · Medpace Holdings
31 filings
MEDP 10-Q Quarterly Reports
Medpace Holdings - 31 quarterly reports
MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.
- 8-K · Aug 16, 2016
- 8-K · Oct 28, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 3, 2016
- 8-K · Dec 8, 2016
- 8-K · Feb 27, 2017
- 8-K · Feb 28, 2017
- 10-K · Feb 28, 2017
- 8-K · May 1, 2017
- 10-Q · May 2, 2017
- 8-K · May 23, 2017
- 8-K · Jun 15, 2017
- 8-K · Jun 21, 2017
- 8-K · Jul 31, 2017
- 10-Q · Aug 1, 2017
- 8-K · Aug 22, 2017
- 8-K · Oct 30, 2017
- 10-Q · Oct 31, 2017
- 8-K · Dec 5, 2017
- 8-K · Feb 26, 2018
- 10-K · Feb 27, 2018
- 8-K · Apr 30, 2018
- 10-Q · May 1, 2018
- 8-K · May 4, 2018
- 8-K · May 23, 2018
- 8-K · Jun 8, 2018
- 8-K · Jun 13, 2018
- 8-K · Jul 30, 2018
- 10-Q · Jul 31, 2018
- 8-K · Aug 6, 2018
- 8-K · Aug 9, 2018
- 8-K · Aug 13, 2018
- 8-K · Aug 24, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 29, 2018
- 10-Q · Oct 30, 2018
- 8-K · Feb 25, 2019
- 10-K · Feb 26, 2019
- 8-K · Apr 16, 2019
- 8-K · Apr 29, 2019
- 10-Q · Apr 30, 2019
- 8-K · May 17, 2019
- 8-K · May 21, 2019
- 8-K · May 24, 2019
- 8-K · Jul 29, 2019
- 10-Q · Jul 30, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 25, 2019
- 8-K · Oct 28, 2019
- 10-Q · Oct 29, 2019
- 8-K · Feb 24, 2020
- 10-K · Feb 25, 2020
- 8-K · Mar 5, 2020
- 8-K · Apr 1, 2020
- 8-K · Apr 28, 2020
- 10-Q · Apr 29, 2020
- 8-K · May 21, 2020
- 8-K · Jul 27, 2020
- 10-Q · Jul 28, 2020
- 8-K · Oct 26, 2020
- 10-Q · Oct 27, 2020
- 8-K · Oct 30, 2020
- 8-K · Feb 16, 2021
- 10-K · Feb 16, 2021
- 8-K · Mar 30, 2021
- 8-K · Apr 26, 2021
- 10-Q · Apr 27, 2021
- 8-K · May 14, 2021
- 8-K · Jun 11, 2021
- 8-K · Jul 23, 2021
- 8-K · Jul 26, 2021
- 8-K · Jul 26, 2021
- 10-Q · Jul 27, 2021
- 8-K · Oct 25, 2021
- 10-Q · Oct 26, 2021
- 8-K · Dec 29, 2021
- 8-K · Feb 14, 2022
- 10-K · Feb 15, 2022
- 8-K · Mar 16, 2022
- 8-K · Apr 25, 2022
- 10-Q · Apr 26, 2022
- 8-K · May 20, 2022
- 8-K · May 26, 2022
- 8-K · Jun 10, 2022
- 8-K · Jul 25, 2022
- 10-Q · Jul 26, 2022
- 8-K · Oct 24, 2022
- 10-Q · Oct 25, 2022
- 8-K · Jan 3, 2023
- 8-K · Jan 18, 2023
- 8-K · Feb 13, 2023
- 10-K · Feb 14, 2023
- 8-K · Mar 31, 2023
- 8-K · Apr 24, 2023
- 10-Q · Apr 25, 2023
- 8-K · May 19, 2023
- 8-K · Jul 24, 2023
- 10-Q · Jul 25, 2023
- 8-K · Oct 23, 2023
- 10-Q · Oct 24, 2023
- 8-K · Feb 12, 2024
- 10-K · Feb 13, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 22, 2024
- 10-Q · Apr 23, 2024
- 8-K · May 21, 2024
- 8-K · Jul 3, 2024
- 8-K · Jul 22, 2024
- 10-Q · Jul 23, 2024
- 8-K · Oct 21, 2024
- 10-Q · Oct 22, 2024
- 8-K · Feb 10, 2025
- 10-K · Feb 11, 2025
- 8-K · Mar 31, 2025
- 8-K · Apr 21, 2025
- 10-Q · Apr 22, 2025
- 8-K · May 16, 2025
- 8-K · Jul 21, 2025
- 10-Q · Jul 22, 2025
- 8-K · Oct 22, 2025
- 10-Q · Oct 23, 2025
- 8-K · Feb 9, 2026
- 10-K · Feb 10, 2026
- 8-K · Apr 22, 2026
- 10-Q · Apr 23, 2026
- 8-K · May 19, 2026
- 8-K · Jun 4, 2026
- 8-K · Jul 22, 2026
- 10-Q · Jul 23, 2026
- 8-K · Oct 21, 2026
- 10-Q · Oct 22, 2026
- 2026-Q3Oct 22, 2026
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2026
Medpace Holdings, Inc. reported third-quarter 2026 revenue, net of $716.0 million, up from $659.9 million in the prior-year quarter, and net income of $137.5 million, compared with $111.1 million. For the nine months ended September 30, 2026, revenue was $2,129.9 million versus $1,821.8 million, and net income was $382.7 million versus $316.0 million. Diluted EPS was $4.84 for the quarter and $13.37 for the nine months. The filing states that growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas. Net new business awards were $873.4 million for the quarter and $2,287.6 million for the nine months, and backlog was $3,167.2 million as of September 30, 2026. The balance sheet strengthened over the period. Cash and cash equivalents rose to $705.3 million from $497.0 million at year-end 2025, and the company had no indebtedness. Operating cash flow was $530.4 million for the nine months. Share repurchases totaled $294.7 million in the nine months, with no repurchases in the third quarter. Effective October 20, 2026, the Board terminated the existing authorization and approved a new repurchase authorization of up to $1.0 billion. The filing also discloses securities class action and derivative lawsuits filed in 2026 relating to statements about the company's book-to-bill ratio. The plaintiffs voluntarily dismissed the actions, without prejudice, in October 2026. Management stated that legal proceedings were immaterial as of September 30, 2026.
- 2026-Q2Jul 23, 2026
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2026
Medpace Holdings, Inc. reported a strong second quarter of 2026, with total revenue of $707.3 million for the three months ended June 30, 2026, up from $603.3 million a year earlier, and $1,413.9 million for the six months, up from $1,161.9 million. Net income was $121.4 million for the quarter versus $90.3 million, and diluted EPS was $4.25 versus $3.10. Growth was attributed primarily to the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose sharply and drove much of the increase in total direct costs. Net new business awards were $795.7 million for the quarter and $1,414.2 million for the six months, and backlog stood at $3,014.2 million as of June 30, 2026. Cash and cash equivalents were $502.7 million at quarter end, and the company has no indebtedness, with a $10.0 million credit facility fully available. Operating cash flow for the first six months was $313.8 million, while the company spent $294.8 million on share repurchases during the period. Shares outstanding fell from 28,370,780 at December 31, 2025 to 27,910,605 at June 30, 2026, and shareholders' equity declined to $433.9 million from $459.1 million. Remaining repurchase authorization totaled $527.0 million. The filing also discloses two shareholder lawsuits filed in April and June 2026 relating to statements about the company's book-to-bill ratio. The company has not recognized a liability for either matter, stating that any potential loss is not currently probable or reasonably estimable.
- 2026-Q1Apr 23, 2026
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2026
Medpace Holdings, Inc. reported net income of $123.9 million for the quarter ended March 31, 2026, up from $114.6 million in the prior-year quarter, with diluted EPS of $4.28 versus $3.67. Revenue, net rose $148.0 million (26.5%) to $706.6 million, driven primarily by growth in the Metabolic, Oncology, Central Nervous System and AVAI therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, rose $109.6 million, and total direct costs increased to $510.3 million from $380.2 million. Selling, general and administrative expenses fell $10.0 million to $47.9 million, mainly due to lower stock-based compensation. The balance sheet strengthened over the quarter. Cash and cash equivalents increased to $652.7 million from $497.0 million at December 31, 2025, and the company reported no indebtedness under its $10.0 million Credit Facility. Operating cash flow was $151.8 million, and shareholders' equity rose to $598.3 million from $459.1 million. The company did not repurchase any shares in the quarter, leaving $821.7 million of remaining authorization, compared with $389.8 million of repurchases in the prior-year quarter. Net new business awards were $618.4 million, and backlog reached $2,929.2 million. A securities class action was filed on April 6, 2026, in the U.S. District Court for the Southern District of Ohio against the company and three officers, alleging materially false and misleading statements about the book-to-bill ratio. The company has recorded no liability for the matter because a loss is not currently probable or reasonably estimable.
- 2025-Q3Oct 23, 2025
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2025
Medpace Holdings, Inc. reported its third-quarter 2025 results in this Form 10-Q for the period ended September 30, 2025. Revenue, net was $659.9 million for the three months ended September 30, 2025, up from $533.3 million a year earlier, and $1.82 billion for the nine months, up from $1.57 billion. Net income was $111.1 million for the quarter (diluted EPS $3.86) and $316.0 million for the nine months (diluted EPS $10.64). Income from operations rose to $141.8 million for the quarter and $381.7 million for the nine months. Net new business awards were $789.6 million for the quarter and $1.91 billion for the nine months, and backlog stood at $3,000.6 million as of September 30, 2025. The balance sheet shows a significant shift in capital allocation. Cash and cash equivalents declined to $285.4 million from $669.4 million at December 31, 2024, primarily due to share repurchases. The company repurchased 2,961,924 shares for $912.9 million during the nine months, leaving $821.7 million of remaining authorization. Total shareholders' equity fell to $293.6 million from $825.5 million, and the accumulated deficit was $(596.2) million compared with retained earnings of $8.2 million at year-end 2024. Net cash from operating activities was $520.6 million for the nine months, and the company reported no indebtedness under its $10.0 million credit facility. The company stated that its disclosure controls and procedures were effective, and it reported no material changes to its market risk disclosures or risk factors relative to its 2024 Form 10-K. Advanced billings increased to $834.3 million, and the company disclosed approximately $3.5 billion of performance obligations remaining on active projects.
- 2025-Q2Jul 22, 2025
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2025
Medpace Holdings, Inc. reported second-quarter 2025 revenue, net of $603.3 million, up from $528.1 million in the prior-year quarter, and net income of $90.3 million versus $88.4 million. For the six months ended June 30, 2025, revenue was $1.16 billion and net income was $204.9 million. Growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas. Backlog was $2,873.6 million as of June 30, 2025, a decrease of $51.3 million, or 1.8%, from $2,924.9 million a year earlier. Net new business awards were $620.5 million for the quarter and $1,120.6 million for the six months. The balance sheet changed significantly in 2025 because of share repurchases. Cash and cash equivalents fell to $46.3 million at June 30, 2025 from $669.4 million at December 31, 2024. The company repurchased $908.4 million of stock in the first half of 2025 and had $826.3 million of remaining authorization at quarter-end. Total shareholders' equity declined to $172.4 million from $825.5 million, and the accumulated deficit reached $703.2 million. The company had no indebtedness at quarter-end. In July 2025 it amended its credit facility to reduce the borrowing limit from $600.0 million to $10.0 million. Profitability was supported by a higher effective tax rate in the quarter of 27.5%, compared with 20.0% a year earlier. Operating cash flow for the six months was $274.4 million. Direct costs and SG&A rose with the growth in service activity, and SG&A for the six months increased 22.2%. The filing also notes that the One Big Beautiful Bill Act was enacted on July 4, 2025, and that management is assessing its impact on the financial statements.
- 2025-Q1Apr 22, 2025
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2025
Medpace Holdings, Inc. reported first-quarter 2025 revenue, net of $558.6 million, up from $511.0 million in the prior-year quarter, with net income of $114.6 million compared to $102.6 million. Income from operations was $113.5 million versus $104.1 million. Diluted earnings per share were $3.67, compared with $3.20 a year earlier. Growth was primarily driven by the Metabolic, Oncology, and Central Nervous System therapeutic areas. Selling, general and administrative expenses rose to $57.9 million from $44.1 million, attributed to higher personnel costs. Net new business awards were $500.0 million versus $615.6 million, and backlog was $2,846.0 million, down 2.1% from $2,907.1 million a year earlier. Capital allocation was the dominant balance sheet event. The company repurchased 1,193,011 shares for $389.8 million during the quarter, and cash and cash equivalents fell to $441.4 million from $669.4 million at December 31, 2024. Shareholders' equity declined to $593.6 million from $825.5 million, and the accumulated deficit was $(269.7) million versus retained earnings of $8.2 million at year-end 2024. The company had no indebtedness at March 31, 2025. On April 17, 2025, the Board approved an additional $1.0 billion repurchase increase, and on April 18, 2025, the credit facility was amended to increase the line of credit to up to $600.0 million. Operating cash flow was $125.8 million, compared with $152.7 million in the prior-year quarter. The effective income tax rate was 3.0%, compared with 9.0% a year earlier, reflecting excess tax benefits from share-based compensation. Total performance obligations remaining were approximately $3.4 billion.
- 2024-Q3Oct 22, 2024
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2024
Medpace Holdings, Inc. reported strong third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024. Total revenue was $533.3 million for the three months ended September 30, 2024, up from $492.5 million a year earlier, and $1.57 billion for the nine months, up from $1.39 billion. Income from operations rose to $112.3 million for the quarter from $84.9 million, and net income was $96.4 million, or $3.01 per diluted share, compared with $70.6 million, or $2.22 per diluted share, in the prior-year quarter. The filing states that growth was driven primarily by the Metabolic, Oncology and Cardiology therapeutic areas. Backlog reached $2,927.4 million as of September 30, 2024, up from $2,689.5 million a year earlier, and net new business awards were $533.7 million for the quarter and $1,700.3 million for the nine months. The company expects roughly $1,610.0 million to $1,630.0 million of backlog to convert to net revenue over the next twelve months. Balance sheet liquidity strengthened considerably. Cash and cash equivalents were $656.9 million at September 30, 2024, up from $245.4 million at December 31, 2023, and the company reported no indebtedness. Net cash provided by operating activities was $418.1 million for the nine months, and no share repurchases were executed during 2024 through September 30, with $308.8 million remaining under the repurchase authorization.
- 2024-Q2Jul 23, 2024
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2024
Medpace Holdings, Inc. reported strong second-quarter 2024 results in its Form 10-Q. Net revenue rose 14.6% to $528.1 million for the three months ended June 30, 2024, from $460.9 million a year earlier, and rose 16.1% to $1,039.1 million for the six months. The filing attributes the growth to Metabolic, Oncology and Other therapeutic areas. Income from operations was $105.2 million for the quarter versus $78.4 million, and net income was $88.4 million versus $61.1 million. Diluted EPS was $2.75 compared with $1.93. For the six months, net income was $190.9 million and diluted EPS was $5.96, versus $134.0 million and $4.20 in the prior-year period. Liquidity strengthened considerably. Cash and cash equivalents increased to $510.9 million from $245.4 million at December 31, 2023, and net cash provided by operating activities was $269.1 million for the six months, compared with $162.6 million. Advanced billings rose to $638.4 million from $559.9 million. The company reported no indebtedness at June 30, 2024, and its credit facility line was reduced to up to $10.0 million. Shareholders' equity increased to $763.6 million, and the accumulated deficit narrowed to $30.8 million from $221.6 million. Forward indicators were mixed. Backlog increased $353.0 million, or 13.7%, to $2,924.9 million, and the company expects approximately $1,575.0 million to $1,595.0 million of that backlog to convert to net revenue over the next twelve months. Net new business awards were $551.0 million in the quarter, compared with $574.8 million a year earlier, and $1,166.5 million for the six months, compared with $1,130.6 million. The company made no share repurchases in the first half of 2024 and had $308.8 million of remaining authorization under its repurchase program.
- 2024-Q1Apr 23, 2024
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2024
Medpace Holdings, Inc. reported first-quarter 2024 revenue, net of $511.0 million, up from $434.1 million in the first quarter of 2023, with the filing stating the increase was broad based but primarily driven by the Metabolic, Oncology, AVAI and Other therapeutic areas. Income from operations was $104.1 million versus $86.2 million a year earlier, and net income was $102.6 million, compared with $72.9 million. Diluted EPS was $3.20 versus $2.27. The effective tax rate fell to 9.0% from 15.3%, which the company attributed mainly to excess tax benefits from share-based compensation and Foreign Derived Intangible Income benefits. Backlog rose to $2,907.1 million as of March 31, 2024, up $447.0 million, or 18.2%, from $2,460.1 million a year earlier. Net new business awards were $615.6 million for the quarter, compared with $555.8 million in the prior-year quarter. Net cash provided by operating activities was $152.7 million, helped by a $56.8 million increase in advanced billings. Cash and cash equivalents rose to $407.0 million from $245.4 million at December 31, 2023. The company made no share repurchases in the quarter, leaving $308.8 million of authorization under its $500.0 million program. It had no indebtedness at March 31, 2024. The credit facility was reduced to a $10.0 million revolving line, with $10.0 million available for borrowing. Shareholders' equity increased to $671.5 million from $558.9 million.
- 2023-Q3Oct 24, 2023
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2023
Medpace Holdings, Inc. reported strong growth in its third quarter ended September 30, 2023. Total revenue, net was $492.5 million for the three months ended September 30, 2023, up from $383.7 million a year earlier, and $1,387.4 million for the nine months, up from $1,065.9 million. Income from operations rose to $84.9 million for the quarter from $77.8 million, and net income was $70.6 million, compared with $66.0 million in the prior-year quarter. Diluted EPS was $2.22 for the quarter versus $2.05, and $6.42 for the nine months versus $5.18. The filing attributes revenue growth primarily to Oncology, Metabolic, AVAI and other therapeutic areas. Backlog was $2,689.5 million as of September 30, 2023, and net new business awards were $611.5 million for the quarter and $1,742.1 million for the nine months. Balance sheet and cash flow strengthened over the period. Cash and cash equivalents rose to $95.2 million from $28.3 million at December 31, 2022, and the company reported no indebtedness as of September 30, 2023, after repaying its short-term debt. Net cash provided by operating activities was $277.0 million for the nine months, versus $251.4 million a year earlier. The company repurchased 781,068 shares for $144.0 million in the nine months ended September 30, 2023, and did not repurchase shares in the third quarter. Remaining authorization under the new $500.0 million repurchase program was $308.8 million. The company's effective tax rate was 15.2% for the quarter and 16.5% for the nine months. Management concluded that disclosure controls and procedures were effective, and no material changes were reported to market risk or risk factors versus the 2022 Form 10-K.
- 2023-Q2Jul 25, 2023
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2023
Medpace Holdings, Inc. reported second-quarter 2023 total revenue, net of $460.9 million, up from $351.2 million in the three months ended June 30, 2022, with net income of $61.1 million versus $49.4 million. For the six months ended June 30, 2023, revenue was $894.9 million and net income was $134.0 million, compared with $682.2 million and $110.7 million a year earlier. Income from operations rose to $164.6 million for the six-month period from $124.4 million. Diluted EPS was $1.93 for the quarter and $4.20 for the six months, compared with $1.46 and $3.16 in the prior-year periods. Net new business awards were $574.8 million for the quarter and $1,130.6 million for the six months, and backlog reached $2,571.9 million as of June 30, 2023, up from $2,168.3 million a year earlier. The filing states that approximately $1,410.0 million to $1,430.0 million of backlog is expected to convert to net revenue over the next twelve months. The company also disclosed approximately $2.9 billion of performance obligations remaining for active projects. On the balance sheet, cash and cash equivalents were $39.1 million and short-term debt was $55.0 million at June 30, 2023. Operating cash flow for the six months was $162.6 million, and the company repurchased $144.0 million of common stock during the period, with $308.8 million of authorization remaining under its new program. The company also amended its credit facility on March 31, 2023, reducing the maximum borrowing to $150.0 million.
- 2023-Q1Apr 25, 2023
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2023
Medpace Holdings, Inc. reported first-quarter 2023 revenue, net of $434.1 million, up from $330.9 million in the first quarter of 2022, with net income of $72.9 million compared to $61.3 million a year earlier. Diluted earnings per share were $2.27, versus $1.69. Income from operations was $86.2 million, and the effective income tax rate rose to 15.3% from 6.1%. Growth was primarily driven by Oncology, Metabolic, Cardiology and other therapeutic areas. Total direct costs rose to $303.9 million, including reimbursed out-of-pocket expenses of $152.8 million, which the filing notes can fluctuate significantly from period to period. Net new business awards were $555.8 million for the quarter, compared with $423.0 million a year earlier. Backlog was $2,460.1 million as of March 31, 2023, and the filing states that approximately $1,320.0 million to $1,340.0 million is expected to convert to net revenue over the next twelve months. The company also disclosed approximately $2.9 billion of performance obligations remaining for active projects. Capital allocation was active: the company repurchased 654,787 shares for $120.1 million during the quarter, leaving $332.7 million of authorization under a $500.0 million program approved in the fourth quarter of 2022. Cash rose to $46.9 million, while short-term debt increased to $115.0 million from $50.0 million, and total shareholders' equity fell to $347.3 million from $386.4 million. The company amended its credit facility on March 31, 2023, reducing the borrowing capacity to up to $150.0 million and extending its expiration to March 29, 2024.
- 2022-Q3Oct 25, 2022
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2022
Medpace Holdings, Inc. reported strong top-line growth in the third quarter of 2022. Net revenue was $383.7 million for the three months ended September 30, 2022, up $88.2 million, or 29.8%, from $295.6 million a year earlier. For the nine months, net revenue was $1,065.9 million, up 27.8% from $833.8 million. Net income rose to $66.0 million for the quarter (diluted EPS of $2.05, versus $1.29) and to $176.7 million for the nine months (diluted EPS of $5.18, versus $3.49). The filing attributes revenue growth primarily to Oncology, Metabolic, Cardiology and Central Nervous System therapeutic areas. Backlog increased 20.9% to $2,236.2 million as of September 30, 2022, and net new business awards were $470.9 million for the quarter and $1,344.4 million for the nine months. Capital allocation dominated the balance sheet. During the nine months, the company repurchased 5,463,244 shares for $800.5 million and has now completed all authorized repurchases under its program. Cash and cash equivalents fell to $31.0 million from $461.3 million at December 31, 2021, and the company drew $139.7 million on its revolving credit facility, which is classified as short-term debt. Total shareholders' equity declined to $349.9 million from $952.9 million, and the company reported an accumulated deficit of $(380.1) million compared with retained earnings of $235.0 million at year-end 2021. Operating cash flow was $251.4 million for the nine months, and $110.1 million was available for borrowing under the credit facility. The filing also highlights new risk factor language on operating margins, which could decrease due to competitive or inflationary pricing pressure. It adds risk factor discussion on international operations, including the conflict involving Russia and Ukraine, and notes that the COVID-19 pandemic continues to disrupt clinical sites and trial enrollment. Management stated that the future financial impact of the pandemic cannot be reasonably estimated. Total performance obligations remaining for active projects were approximately $2.5 billion as of September 30, 2022.
- 2022-Q2Jul 26, 2022
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2022
Medpace Holdings, Inc. reported strong second-quarter 2022 results, with revenue of $351.2 million for the three months ended June 30, 2022, up from $278.3 million a year earlier, and net income of $49.4 million versus $39.9 million. For the six months, revenue was $682.2 million and net income was $110.7 million, with diluted earnings per share of $3.16 compared with $2.20. The filing states that the increase was primarily driven by growth in the Oncology, Metabolic, Cardiology and Central Nervous System therapeutic areas. Net new business awards were $450.6 million for the quarter and $873.6 million for the six months, and backlog reached $2,168.3 million as of June 30, 2022. The balance sheet shifted sharply during the first half of 2022. Cash and cash equivalents fell to $42.6 million from $461.3 million at December 31, 2021, primarily because of share repurchases. The company bought back $800.5 million of stock in the first six months, and it completed all authorized repurchases under its program as of June 30, 2022. Shareholders' equity declined to $283.3 million from $952.9 million, and the accumulated deficit reached $446.1 million, reflecting retirement of repurchased shares in excess of par value. To fund the buybacks, the company drew $299.2 million on its revolving credit facility, leaving $249.7 million of short-term debt outstanding, which is due in 2023. The Credit Facility's capacity was increased to $250.0 million, and the filing states that only $0.1 million was available for borrowing as of June 30, 2022. Operating cash flow was $142.9 million for the six months, up from $120.1 million. Management attributed the rise in direct costs mainly to higher reimbursed out-of-pocket expenses and personnel costs. The filing also flags that COVID-19 and the conflict involving Russia and Ukraine remain sources of uncertainty, and it adds a risk factor on operating margin pressure from competitive pricing and inflation.
- 2022-Q1Apr 26, 2022
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2022
Medpace Holdings, Inc. reported first-quarter 2022 revenue, net of $330.9 million, up from $260.0 million in the prior-year quarter, with net income of $61.3 million versus $43.3 million. Income from operations was $64.2 million compared with $47.6 million, and diluted earnings per share were $1.69 versus $1.14. Growth was primarily driven by the Oncology, Metabolic, Central Nervous System and Cardiology therapeutic areas. Net new business awards were $423.0 million for the quarter, and backlog rose to $2,088.0 million at March 31, 2022, from $1,631.8 million a year earlier. The balance sheet changed significantly because of capital returns. Cash and cash equivalents fell to $82.8 million from $461.3 million at December 31, 2021, after the company repurchased 2,745,865 shares for $425.9 million during the quarter. Shareholders' equity declined to $605.0 million from $952.9 million, and retained earnings turned to an accumulated deficit of $(120.8) million. Remaining repurchase authorization was $264.6 million at March 31, 2022. The company had no borrowings under its Credit Facility, which was increased to up to $250.0 million in March 2022. Operating cash flow was $46.3 million, compared with $57.3 million in the prior-year quarter, reflecting a $38.2 million increase in accounts receivable and unbilled. The effective tax rate was 6.1%, versus 10.7% a year earlier. The filing states that COVID-19 continues to disrupt the business and that the impact of the Russia-Ukraine conflict is also a risk factor.
- 2021-Q3Oct 26, 2021
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2021
Medpace Holdings, Inc. reported third-quarter 2021 results in this Form 10-Q, with revenue, net of $295.6 million for the three months ended September 30, 2021, up from $230.4 million a year earlier, and $833.8 million for the nine months, up from $666.2 million. Income from operations was $53.7 million for the quarter versus $46.4 million, and net income was $48.6 million, or $1.29 per diluted share, compared with $41.5 million and $1.09 per diluted share in the prior-year quarter. For the nine months, net income was $131.8 million, or $3.49 per diluted share. The filing states that revenue growth was primarily driven by Oncology, Metabolic and Central Nervous System therapeutic areas, and that the effective tax rate for the nine months fell to 9.7% from 17.0%, largely due to excess tax benefits from share-based compensation. Backlog reached $1,849.8 million at September 30, 2021, up from $1,434.4 million a year earlier, and net new business awards were $1,151.7 million for the nine months. The company held $398.4 million in cash and cash equivalents, had no borrowings under its $50.0 million unsecured Credit Facility, and generated $192.4 million in operating cash flow for the nine months. It repurchased $62.1 million of common stock during the nine months, leaving $190.5 million of remaining authorization under the program. The filing notes that COVID-19 had a significant adverse effect on results and may have a continued impact, and that its future financial effect cannot be reasonably estimated. Related-party transactions with entities linked to the chief executive officer, including headquarters and Cincinnati office leases and clinical services revenue from LIB Therapeutics and CinRx, are disclosed in the notes.
- 2021-Q2Jul 27, 2021
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2021
Medpace Holdings, Inc. reported strong second-quarter 2021 results, with revenue, net of $278.3 million for the three months ended June 30, 2021, up from $205.0 million a year earlier, and net income of $39.9 million, compared with $24.1 million. For the six months ended June 30, 2021, revenue, net was $538.3 million and net income was $83.2 million. Diluted earnings per share were $1.06 for the quarter and $2.20 for the six months. The company's net new business awards were $387.6 million for the quarter and $743.7 million for the six months, and backlog rose to $1,742.6 million as of June 30, 2021, from $1,342.8 million a year earlier. The filing states that the COVID-19 pandemic had a significant adverse effect on results of operations in the period and may continue to have an adverse impact in the future. The balance sheet remained solid, with cash and cash equivalents of $339.0 million, no outstanding borrowings under the $50.0 million Credit Facility, and total shareholders' equity of $851.9 million as of June 30, 2021. Net cash provided by operating activities was $120.1 million for the six months, while the company repurchased $55.9 million of common stock in cash during the period. In the second quarter of 2021, the Board approved a $150.0 million increase to the repurchase program, bringing total authorization to $300.0 million, with $196.4 million remaining as of June 30, 2021. The filing shows that growth was driven primarily by Oncology, Central Nervous System, Metabolic and other therapeutic areas in the quarter. Total direct costs rose with higher reimbursed out-of-pocket expenses and personnel costs. The effective tax rate fell to 6.4% for the quarter and 8.7% for the six months, versus 20.6% in the prior-year periods, primarily due to excess tax benefits from share-based compensation and Foreign Derived Intangible Income benefits.
- 2021-Q1Apr 27, 2021
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2021
Medpace Holdings, Inc. reported net income of $43.3 million on revenue, net of $260.0 million for the three months ended March 31, 2021, compared with net income of $29.0 million and revenue of $230.9 million in the same period of 2020. Revenue increased by $29.1 million, driven primarily by growth in the Oncology, AVAI and other uncategorized therapeutic areas. Income from operations was $47.6 million versus $35.5 million a year earlier, and diluted earnings per share were $1.14 compared with $0.76. The effective tax rate fell to 10.7% from 20.6%, mainly due to higher tax benefits related to Foreign Derived Intangible Income and excess tax benefits from share-based compensation. The balance sheet strengthened over the quarter. Cash and cash equivalents rose to $332.9 million from $277.8 million at December 31, 2020, and the company had no outstanding borrowings under its $50.0 million Credit Facility, which was extended to March 31, 2022. Net cash provided by operating activities was $57.3 million, supported by a $22.1 million increase in advanced billings. Backlog increased to $1,631.8 million from $1,294.2 million a year earlier, and net new business awards were $356.2 million, compared with $246.9 million in the prior-year quarter. Management said the COVID-19 pandemic had a significant adverse effect on results and may continue to affect operations, and that its future financial impact cannot be reasonably estimated. During the quarter the company made no share repurchases, against $43.2 million of repurchases in the first quarter of 2020. As of March 31, 2021, $102.6 million remained under the repurchase authorization. Shares outstanding increased to 35,926,158 from 35,519,989, reflecting stock option exercises.
- 2020-Q3Oct 27, 2020
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2020
Medpace Holdings, Inc. reported third-quarter 2020 results with net revenue of $230.4 million, up from $216.2 million in the prior-year quarter, and net income of $41.5 million, or $1.09 per diluted share, compared with $24.0 million, or $0.63 per diluted share, a year earlier. For the nine months ended September 30, 2020, revenue was $666.2 million and net income was $94.5 million, or $2.50 per diluted share. The filing states that the COVID-19 pandemic has had a significant adverse effect on the first three quarters of fiscal 2020 and is expected to have a continued adverse impact, with the company stating that the future financial impact "cannot be reasonably estimated, but the impact will likely be material." The balance sheet strengthened over the period. Cash and cash equivalents rose to $219.2 million at September 30, 2020 from $131.9 million at December 31, 2019, and the company reported no indebtedness under its $50.0 million unsecured Credit Facility. Net cash provided by operating activities was $153.2 million for the nine months ended September 30, 2020. The company repurchased 772,125 shares for $50.8 million during the nine months, with $49.2 million remaining under its authorization, and reported net new business awards of $816.4 million for the nine months. Backlog was $1,434.4 million at September 30, 2020, up from $1,228.7 million a year earlier. The filing also notes that the company had approximately 3,400 employees across 39 countries as of September 30, 2020, and that it implemented some staff reductions in response to the expected pandemic impact. Related-party transactions are significant and disclosed in detail, including leases with entities owned by the chief executive officer and services provided to entities in which executives have interests.
- 2020-Q2Jul 28, 2020
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2020
Medpace Holdings, Inc. reported second-quarter 2020 revenue, net of $204.995 million, down $9.1 million from $214.104 million in the prior-year quarter, with the filing attributing the decline primarily to the impact of the COVID-19 pandemic on operations. Net income for the quarter was $24.104 million, or $0.64 per diluted share, compared with $27.455 million, or $0.73 per diluted share, a year earlier. For the six months ended June 30, 2020, revenue rose $21.029 million to $435.874 million, driven by growth in the Oncology and AVAI therapeutic areas, and net income was $53.058 million. The balance sheet remained strong, with cash and cash equivalents of $160.903 million at June 30, 2020, up from $131.920 million at year-end 2019, and no outstanding borrowings under the $50.0 million Credit Facility. Net cash provided by operating activities was $93.415 million for the six months. The company repurchased 772,125 shares for $50.8 million during the first half, and $49.2 million remained available under the repurchase authorization. Net new business awards were $254.1 million for the quarter, and backlog was $1,342.8 million at June 30, 2020. Management stated that the pandemic has had a significant adverse effect on the first and second quarters of 2020, that the impact will likely be material, and that the future financial impact cannot be reasonably estimated. For investors, the key tensions are a near-term revenue decline and management's explicit warning of continued adverse effects from COVID-19, set against a debt-free balance sheet, growing backlog, and ongoing share repurchases.
- 2020-Q1Apr 29, 2020
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2020
Medpace Holdings, Inc. filed this Form 10-Q for the quarter ended March 31, 2020. Revenue, net rose to $230.9 million from $200.7 million in the prior-year quarter, and net income increased to $29.0 million from $19.2 million. Diluted EPS was $0.76 versus $0.51. The filing states that the primary growth drivers were Oncology, AVAI and other therapeutic areas, with higher reimbursed out-of-pocket expenses and personnel costs accompanying the expansion. Net new business awards were $246.9 million and backlog reached $1,294.2 million, up from $1,108.1 million a year earlier. The balance sheet remains conservative. Cash and cash equivalents were $134.0 million at quarter end, the company had no outstanding borrowings under its $50.0 million Credit Facility, and shareholders' equity was $717.8 million. During the quarter the company repurchased 661,637 shares for $43.2 million, leaving $56.8 million available under its repurchase authorization. Management states that the COVID-19 pandemic has already significantly adversely affected first-quarter results and will have an increasing adverse impact going forward, with the future financial impact described as likely to be material but not reasonably estimable. The filing notes reduced trial starts, slowed new business awards, possible study cancellations, and some staff reductions in certain geographies.
- 2019-Q3Oct 29, 2019
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2019
Medpace Holdings, Inc. reported third-quarter 2019 revenue, net of $216.2 million, up from $179.3 million in the year-earlier period, and nine-month revenue of $631.1 million versus $512.5 million. Income from operations was $30.0 million for the quarter ($26.9 million prior year) and net income was $24.0 million, or $0.63 diluted EPS, compared with $19.3 million and $0.52 a year earlier. For the nine months, net income was $70.6 million, or $1.88 diluted EPS. The filing states that growth was primarily driven by Oncology and other therapeutic areas, and that total direct costs rose with higher reimbursed out-of-pocket expenses and personnel costs. Backlog stood at $1,228.7 million as of September 30, 2019, up from $1,024.5 million a year earlier, and net new business awards were $285.4 million for the quarter and $813.3 million for the nine months. Approximately $675 million to $695 million of backlog is expected to convert to net revenue over the next twelve months. The company ended the quarter with $79.3 million in cash and no indebtedness, after repaying its prior senior secured term loan and entering into a new unsecured $50.0 million credit facility on September 30, 2019. The filing also discloses that management concluded internal control over financial reporting was not effective as of September 30, 2019, due to a material weakness related to the implementation of ASU 2014-09 (Topic 606), which the company is remediating. Operating cash flow was $144.9 million for the nine months, and the effective tax rate was 18.6% for the quarter.
- 2019-Q2Jul 30, 2019
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2019
Medpace Holdings, Inc. reported second-quarter 2019 net revenue of $214.1 million, up $44.0 million, or 25.8%, from $170.1 million in the second quarter of 2018. Income from operations rose to $35.3 million from $23.3 million, and net income increased to $27.5 million from $16.6 million. Diluted earnings per share were $0.73, compared with $0.45 a year earlier. For the six months ended June 30, 2019, net revenue was $414.8 million, up 24.5%, and net income was $46.7 million. The growth was driven primarily by the Oncology and other therapeutic areas, according to the filing. Backlog reached $1,171.7 million at June 30, 2019, an increase of $192.0 million, or 19.6%, from $979.7 million a year earlier. Net new business awards were $279.2 million in the quarter and $527.9 million for the six months. The company expects approximately $665 million to $685 million of backlog to convert to net revenue over the next twelve months. Performance obligations remaining on active projects totaled approximately $1,286.6 million. The balance sheet changed materially during the period. Medpace paid off its remaining term loan obligations, with $80.4 million in principal payments in the six months, and reported no indebtedness at June 30, 2019. Cash and cash equivalents were $20.1 million, and $149.8 million was available under the revolving credit facility. Management concluded that internal control over financial reporting was not effective as of June 30, 2019, due to a material weakness related to the implementation of ASU No. 2014-09 (Topic 606), which the company is remediating.
- 2019-Q1Apr 30, 2019
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2019
Medpace Holdings, Inc., a global provider of clinical research-based drug and medical device development services, reported first-quarter 2019 net revenue of $200.7 million, up from $163.1 million in the prior-year quarter, with the filing attributing the increase primarily to growth in the Oncology, Metabolic and other therapeutic areas. Income from operations rose to $25.9 million from $20.1 million, and net income increased to $19.2 million from $14.6 million. Diluted earnings per share were $0.51 compared with $0.40 a year earlier. Net new business awards were $248.7 million for the quarter, and backlog reached $1,108.1 million at March 31, 2019, of which approximately $615 million to $635 million is expected to convert to net revenue over the next twelve months. Cash flow from operations was $34.0 million, compared with $23.3 million in the prior-year period. The company used $24.0 million to pay down its Senior Secured Term Loan Facility, leaving total indebtedness at $56.4 million and cash and cash equivalents at $30.1 million. The $149.8 million of availability under the revolving credit facility was unchanged in the sense of no borrowings outstanding. The company adopted ASC 842 on January 1, 2019, recognizing $53.6 million of operating lease right-of-use assets and $55.6 million of total operating lease liabilities at March 31, 2019. The filing states that management concluded internal control over financial reporting was not effective as of March 31, 2019, due to a material weakness related to the implementation of ASC 606 (ASU 2014-09), which the company is remediating. Investors should weigh this disclosure alongside the strong revenue, earnings and backlog growth reported for the quarter.
- 2018-Q3Oct 30, 2018
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2018
Medpace Holdings, Inc. reported third-quarter 2018 results under ASC 606, which it adopted on January 1, 2018 using the modified retrospective method. Revenue, net was $179.3 million for the three months ended September 30, 2018 and $512.5 million for the nine months, compared with total revenue of $110.6 million and $323.5 million in the prior-year periods. Net income was $19.3 million ($0.52 diluted EPS) for the quarter, versus $9.8 million ($0.25 diluted) a year earlier, and $50.4 million ($1.36 diluted) for the nine months, versus $27.8 million ($0.69 diluted). The company states that the ASC 606 adoption drove $36.2 million of the quarterly revenue increase and $109.1 million of the nine-month increase. On an ASC 605 basis, the company presents revised quarterly net income of $24.0 million and nine-month net income of $59.1 million. Backlog on an ASC 606 basis was $1,024.5 million at September 30, 2018. Net new business awards were $227.6 million for the quarter and $668.3 million for the nine months on that basis. Cash flow from operations was $117.1 million for the nine months, up from $68.7 million, while total indebtedness fell to $114.5 million from $222.5 million at year-end 2017 (revolver and term loan combined), reflecting $70.0 million of revolver repayments and $38.2 million of term loan payments during the period. A notable governance change occurred on August 10, 2018, when Cinven's secondary offering terminated the voting agreement with CEO and founder Dr. August J. Troendle, and the company ceased to be a Nasdaq 'controlled company.' The company now has a phase-in period to comply with independence requirements, and it currently has no nominating and corporate governance committee.
- 2018-Q2Jul 31, 2018
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2018
Medpace Holdings, Inc. reported strong second-quarter 2018 results in its Form 10-Q filed July 31, 2018. Total revenue was $170.1 million for the three months ended June 30, 2018 and $333.2 million for the six months, with net income of $16.6 million and $31.1 million, respectively. The company adopted ASC 606 on January 1, 2018 using the modified retrospective method, and the filing presents results both as reported under ASC 606 and as revised under ASC 605. Under ASC 605, the revised six-month total revenue would have been $260.3 million and net income $35.1 million. Operating cash flow was $64.6 million for the six months, versus $29.7 million a year earlier. Backlog on an ASC 606 basis was $979.7 million at June 30, 2018, and net new business awards were $239.9 million for the quarter and $440.7 million for the six months. On an ASC 605 basis, backlog was $583.6 million, up $87.7 million, or 17.7%, from a year earlier. The company repaid $50.0 million on its revolving credit facility and $8.3 million on its term loan during the six months, reducing total indebtedness to $164.4 million from $222.1 million at year-end 2017. Cash and cash equivalents were $22.2 million at June 30, 2018. Cinven Capital Management sold 6,000,000 shares of common stock in two secondary offerings during the period, and Cinven owned 29.3% of outstanding common stock as of June 30, 2018. The company did not receive any proceeds from these offerings. Investors should note that the ASC 606 adoption materially changes the reported revenue and cost lines, so period comparisons require reference to the ASC 605 revised figures.
- 2018-Q1May 1, 2018
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2018
Medpace Holdings, Inc. and its subsidiaries, a global provider of clinical research-based drug and medical device development services, reported first-quarter 2018 results in this Form 10-Q. Under the newly adopted ASC 606 revenue standard (modified retrospective method, effective January 1, 2018), total revenue was $163.1 million, compared with $106.6 million in the first quarter of 2017. The filing states that the ASC 606 adoption drove an increase of $39.6 million in revenue. On an ASC 605 basis, total revenue was $123.4 million and net income was $16.3 million, versus $8.4 million a year earlier. Reported net income for the quarter was $14.6 million, or $0.40 per diluted share, compared with $8.4 million, or $0.20 per diluted share, in the prior-year period. Profitability and cash flow improved. Income from operations was $20.1 million, and the effective tax rate fell to 17.6% from 38.7%, which the company attributes mainly to the Tax Cuts and Jobs Act and favorable uncertain tax positions. Operating cash flow was $23.3 million, compared with an outflow of $0.7 million a year earlier. The company used $20.0 million to pay down its revolving credit facility and $4.1 million on its term loan, leaving total indebtedness at $198.5 million. Cash and cash equivalents were $22.2 million at March 31, 2018. The filing reports approximately $915 million of remaining performance obligations on active projects. On an ASC 605 basis, backlog rose 13.1% to $547.3 million, and net new business awards were $128.2 million, compared with $93.9 million in the prior-year quarter. The balance sheet strengthened, with shareholders' equity of $511.1 million, up from $503.5 million at year-end 2017. Accounts receivable and unbilled rose to $110.7 million, and advanced billings rose to $126.4 million. The filing notes that the company's disclosure controls were effective, and that it implemented material changes to its revenue recognition processes in connection with the ASC 606 adoption.
- 2017-Q3Oct 31, 2017
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2017
Medpace Holdings, Inc. reported third-quarter 2017 results with total revenue of $110.6 million, up from $107.8 million a year earlier, and net income of $9.8 million, or $0.25 per diluted share, compared with $5.0 million, or $0.13 per diluted share, in the prior-year quarter. Service revenue, net rose $3.9 million to $98.7 million, driven by growth in the Oncology, Metabolic, and other uncategorized therapeutic areas. Income from operations was $17.2 million versus $12.6 million, helped by a $3.2 million decline in amortization expense. Backlog was $510.0 million at September 30, 2017, up $29.6 million, or 6.2%, from $480.4 million a year earlier, and management expects approximately $275 million to $285 million of it to convert to net service revenue over the next twelve months. Capital allocation was a major theme in the nine months ended September 30, 2017. The company repurchased 2,000,000 shares from Cinven for approximately $60.5 million ($30.27 per share), funded with cash on hand and $40.0 million of revolver borrowings, and repurchased a further 1,342,786 shares for $34.7 million under its $50.0 million program. Cash used in financing activities was $74.6 million for the period, and cash and cash equivalents fell to $24.2 million from $37.1 million at year-end 2016. Total indebtedness was $185.7 million, including $30.0 million drawn on the $150.0 million revolving credit facility. Net cash provided by operating activities was $68.7 million for the nine months ended September 30, 2017, versus $62.7 million a year earlier. Shareholders' equity declined to $550.3 million from $610.7 million, reflecting the share repurchases. The company also acquired the tax attributes of NephroGenex, Inc. out of bankruptcy, recording a $21.4 million deferred credit that will be recognized within the income tax provision over time.
- 2017-Q2Aug 1, 2017
Medpace Holdings Quarterly Report for Q2 Ended Jun 30, 2017
Medpace Holdings, Inc. reported second-quarter 2017 results in this Form 10-Q for the period ended June 30, 2017. Total revenue for the three months rose to $106.2 million from $106.0 million a year earlier, with service revenue, net increasing to $94.6 million from $92.6 million. Net income for the quarter was $9.6 million, or $0.23 per diluted share, compared with $5.0 million, or $0.15 per diluted share, in the prior-year quarter. For the six months, total revenue was $212.8 million and net income was $18.0 million, or $0.44 per diluted share. Income from operations for the six months was $32.2 million, up from $27.0 million, supported by lower amortization and interest expense. Backlog stood at $495.9 million as of June 30, 2017, up $30.2 million, or 6.5%, from $465.7 million a year earlier. Net new business awards were $105.3 million for the quarter and $199.2 million for the six months. Operating cash flow for the six months was $29.7 million, and the company repurchased 1,042,455 shares for $26.4 million under a $50.0 million authorization approved in April 2017. Total indebtedness was $158.8 million at June 30, 2017, with $149.8 million available under the revolving credit facility. The filing also discloses that the company acquired NephroGenex, Inc. out of bankruptcy in May 2017 in an asset purchase that produced $22.2 million of deferred tax assets and a $21.4 million deferred credit. Separately, Cinven-affiliated entities pledged 22,999,997 shares, about 56.4% of outstanding common stock, as collateral for a $150.0 million loan, a development the filing notes could affect controlled-company status if foreclosure occurred.
- 2017-Q1May 2, 2017
Medpace Holdings Quarterly Report for Q1 Ended Mar 31, 2017
Medpace Holdings, Inc. and subsidiaries reported first-quarter 2017 results in this Form 10-Q. Total revenue rose to $106.6 million from $99.6 million, driven by service revenue, net of $93.8 million (up from $87.8 million), which the filing attributes primarily to growth in the Cardiovascular, Oncology, and AVAI therapeutic areas. Income from operations was $15.9 million versus $12.9 million, and net income was $8.4 million, or $0.20 per diluted share, compared with $3.4 million, or $0.11, a year earlier. Interest expense, net fell to $1.8 million from $6.0 million, reflecting lower average borrowings and a lower effective rate under the credit agreement entered into in December 2016. Cash flow was weaker. Net cash used in operating activities was $0.7 million, compared with $12.6 million provided in the prior-year quarter, mainly due to a $10.5 million decrease in accrued expenses and a $5.2 million decrease in advanced billings. Cash, cash equivalents and restricted cash ended the quarter at $29.6 million. Total indebtedness was $161.9 million, substantially all under the Senior Secured Term Loan Facility, and the $150.0 million revolving facility was undrawn. Backlog rose to $483.8 million from $448.1 million a year earlier, and net new business awards were $93.9 million versus $106.4 million. Subsequent to quarter-end, on April 27, 2017, the Board authorized a share repurchase program of up to $50.0 million of common stock. The filing also discloses several related-party arrangements, including service revenue from Coherus BioSciences of $3.3 million, down from $7.1 million, and the purchase of real estate from an entity wholly owned by the chief executive officer for $355,500 thousand's equivalent of $355.5 thousand.
- 2016-Q3Nov 3, 2016
Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2016
Medpace Holdings, Inc. (MEDP) reported third-quarter 2016 results in this Form 10-Q, filed following its August 2016 initial public offering. Total revenue for the three months ended September 30, 2016 was $107.8 million, up from $92.1 million a year earlier, and net income was $5.0 million versus a net loss of $0.1 million. For the nine months, total revenue was $313.3 million and net income was $13.4 million, compared with a net loss of $0.1 million in the prior-year period. Service revenue, net rose to $94.8 million for the quarter and $275.2 million for the nine months, which the company attributed primarily to strong activity in the Oncology, AVAI and Cardiovascular therapeutic areas. Backlog was $480.4 million at September 30, 2016, compared with $421.4 million a year earlier. The IPO closed on August 16, 2016 at $23.00 per share, raising net proceeds of about $173.6 million. Together with cash on hand, the proceeds were used to repay $175.0 million of term loan borrowings, and the company paid down an additional $35.0 million after the IPO. Total indebtedness fell to $165.0 million at September 30, 2016 from $390.0 million at December 31, 2015, and the company had $60.0 million undrawn under its revolving credit facility. Cash and cash equivalents were $14.6 million at quarter-end, and the company stated it was in compliance with all covenants. The balance sheet remains dominated by goodwill of $661.0 million and intangible assets of $148.7 million, together 82.9% of total assets as stated in the risk factors. Cinven and CEO Dr. August J. Troendle together control a substantial majority of the common stock, and the company is a 'controlled company' under NASDAQ rules. Management concluded that disclosure controls were effective as of September 30, 2016.